Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases
IntroductionRituximab (RTX) is a monoclonal antibody targeting CD20, a transmembrane protein expressed on B cells, causing B cell depletion. RTX has shown great efficacy in studies of pemphigus vulgaris, but data of pemphigoid diseases are limited.ObjectiveTo assess the effectiveness and safety of R...
Main Authors: | Aniek Lamberts, H. Ilona Euverman, Jorrit B. Terra, Marcel F. Jonkman, Barbara Horváth |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-02-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fimmu.2018.00248/full |
Similar Items
-
Alterations of Total Serum Immunoglobulin Concentrations in Pemphigus and Pemphigoid: Selected IgG2 Deficiency in Bullous Pemphigoid
by: Stanislav Khil'chenko, et al.
Published: (2020-09-01) -
Immunologic overlap in a case of linear IgG/IgA bullous dermatosis responsive to rituximab
by: Dmitry Nedosekin, PhD, et al.
Published: (2021-03-01) -
Immunoglobulin M bullous pemphigoid: An enigma
by: Rosalie Baardman, MD, et al.
Published: (2020-06-01) -
Proteases in Pemphigoid Diseases
by: Sho Hiroyasu, et al.
Published: (2019-06-01) -
Diffuse blistering rash with ocular involvement
by: Margulies, S., et al.
Published: (2022)